Citigroup’s Immunocore IMCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$754K Hold
25,000
﹤0.01% 3296
2025
Q4
$868K Sell
25,000
-49,600
-66% -$1.75M ﹤0.01% 3223
2025
Q3
$2.71M Sell
74,600
-30,000
-29% -$1.02M ﹤0.01% 2417
2025
Q2
$3.28M Buy
104,600
+49,600
+90% +$1.54M ﹤0.01% 2255
2025
Q1
$1.63M Buy
55,000
+30,000
+120% +$900K ﹤0.01% 2890
2024
Q4
$738K Hold
25,000
﹤0.01% 3582
2024
Q3
$778K Hold
25,000
﹤0.01% 3455
2024
Q2
$847K Buy
+25,000
New +$1.28M ﹤0.01% 3027
2024
Q1
Sell
-25,000
Closed -$1.71M 5742
2023
Q4
$1.71M Buy
+25,000
New +$1.3M ﹤0.01% 2377
2023
Q3
Sell
-11,000
Closed -$660K 5722
2023
Q2
$660K Buy
+11,000
New +$628K ﹤0.01% 3163

Other funds holding IMCR

Citigroup's IMCR Position: Q1 2026 in Review

Citigroup reduced its Immunocore (IMCR) stake by 35% in Q1 2026, selling an estimated $77.1K and leaving 4,517 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #4167.

Citigroup first reported a position in IMCR in Q4 2022 and has held it in 14 quarters since. The position peaked at $19.9M in Q2 2025. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • Citigroup held 4,517 shares of Immunocore worth $136K as of Q1 2026.
  • Citigroup sold 2,383 Immunocore shares in Q1 2026, an estimated $77.1K.
  • Immunocore made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4167 holding.
  • Citigroup first reported a position in Immunocore in Q4 2022 and has held it in 14 quarters since.
  • Citigroup's Immunocore position peaked at $19.9M in Q2 2025.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.